Summary of clinical response for patients with prior thalidomide therapy (n = 177)
| Prior treatment with thalidomide . | Response, no. (%) . | |
|---|---|---|
| CR + PR . | CR + PR + MR . | |
| All patients, n = 177 | 41 (23) | 72 (41) |
| Thalidomide | ||
| Refractory,* n = 20 | 6 (30) | 7 (35) |
| Relapsed,† n = 12 | 2 (17) | 3 (25) |
| Sensitive, n = 144 | 33 (23) | 62 (43) |
| Unknown, n = 1 | 0 | 0 |
| Prior treatment with thalidomide . | Response, no. (%) . | |
|---|---|---|
| CR + PR . | CR + PR + MR . | |
| All patients, n = 177 | 41 (23) | 72 (41) |
| Thalidomide | ||
| Refractory,* n = 20 | 6 (30) | 7 (35) |
| Relapsed,† n = 12 | 2 (17) | 3 (25) |
| Sensitive, n = 144 | 33 (23) | 62 (43) |
| Unknown, n = 1 | 0 | 0 |
CR indicates complete response; MR, minimal response; and PR, partial response.
Refractory defined as immediate disease progression (no initial response) in any of the regimen sequences within which they received thalidomide. The definition is consistent with Wang et al.18
Relapsed defined as progression following initial response to any thalidomide-containing regimen.